# TALazoparib and Avelumab as Maintenance Therapy in Platinum-Sensitive Metastatic or Locally Advanced URothelial Carcinoma

> **NCT04678362** · PHASE2 · RECRUITING · sponsor: **Centre Francois Baclesse** · enrollment: 50 (estimated)

## Conditions studied

- Urothelial Carcinoma

## Interventions

- **DRUG:** Talazoparib + Avelumab

## Key facts

- **NCT ID:** NCT04678362
- **Lead sponsor:** Centre Francois Baclesse
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2021-06-01
- **Primary completion:** 2023-07-28
- **Final completion:** 2025-12
- **Target enrollment:** 50 (ESTIMATED)
- **Last updated:** 2025-09-22

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04678362

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04678362, "TALazoparib and Avelumab as Maintenance Therapy in Platinum-Sensitive Metastatic or Locally Advanced URothelial Carcinoma". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04678362. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*